Keybank National Association OH Takes $27.53 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Keybank National Association OH bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 307,689 shares of the medical equipment provider’s stock, valued at approximately $27,526,000. Keybank National Association OH owned about 0.44% of Lantheus as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB bought a new stake in Lantheus during the third quarter valued at about $25,000. Kestra Investment Management LLC bought a new stake in Lantheus during the 4th quarter valued at approximately $27,000. UMB Bank n.a. grew its holdings in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 134 shares during the last quarter. World Investment Advisors LLC bought a new position in Lantheus in the 3rd quarter worth approximately $60,000. Finally, RiverPark Advisors LLC acquired a new position in shares of Lantheus during the third quarter worth approximately $74,000. Institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

LNTH has been the topic of several research analyst reports. JMP Securities restated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, Truist Financial lifted their target price on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $132.86.

Insider Buying and Selling at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.50% of the company’s stock.

Lantheus Stock Performance

Shares of Lantheus stock opened at $98.17 on Wednesday. The firm has a market cap of $6.72 billion, a P/E ratio of 16.33 and a beta of 0.44. The firm’s 50-day simple moving average is $89.97 and its 200-day simple moving average is $96.73. Lantheus Holdings, Inc. has a twelve month low of $56.44 and a twelve month high of $126.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.